ABPI Code support that’s hands-on, practical, signatory-minded, and built for real approvals.
Or connect with me on LinkedIn:
I’m Dr Anzal Qurbain—ABPI Final Medical Signatory and pharmaceutical physician. I help teams create compliant, credible materials faster by improving approval judgement, strengthening evidence logic, and reducing avoidable rework.
About me and why my perspective is different
My work sits at the intersection of Medical Affairs, compliance, marketing, and governance — where decisions actually get tested.
Everything I do at AskAnzal is shaped by one principle: helping teams move faster without creating unnecessary risk.
My background means I don’t just know the ABPI Code — I know how it’s applied when decisions are challenged, perceptions are tested, and scrutiny is real.
Pharmaceutical Physician with frontline Medical Affairs experience
ABPI Final Signatory reviewing job bags, social media, congress materials, and campaigns
Experience working inside UK and global affiliate teams — not just advising from the outside
Regularly analyse PMCPA cases and Code grey areas, not just the written rules
Focused on defensible judgement, not checklist compliance
I’ve worked across global and specialty pharmaceutical organisations including Roche, Pfizer, Novartis, GSK, Glenmark, UCB, Sobi, Merz, Jazz, Astellas, Alnylam, AOP Health and many many more, supporting Medical Affairs and compliance teams with real-world application of the ABPI Code under regulatory scrutiny.
- Signatory-style thinking for Originators, Reviewers, AQPs and Final Signatories
- Job-bag practical: claims, balance, references, and what will get challenged
- Meetings & congress confidence: materials, slides, booths, follow-up and digital
- Governance that sticks: SOPs/WIs, templates, checklists, workflows and audit trails
How i work
Fast, defensible approvals—without the drama.
I bring a calm, structured approach to ABPI decisions—so your team can move quickly, document rationale properly, and avoid last-minute escalation.
Practical review that improves the next cycle
You get clear edits and rationale you can reuse—tightening claims, strengthening references, and improving balance so approvals get easier over time
Governance that protects the brand
From classification to meeting compliance and digital risk, I help you make decisions that stand up to scrutiny—and are simple to explain internally.
FAQ
Frequently Asked Questions
ABPI signatory-style review and advisory across UK/IE materials—job bags, emails, websites, banners, meetings/congress activity, advisory boards, press releases, and digital/social content. I also deliver workshops and build SOP/WI governance where teams need standardisation.
Yes. AskAnzal is designed for cross-functional teams. The goal is shared decision-making: clearer rationale, fewer review loops, and stronger, defensible outputs.
Book a 30-minute call. Bring one example (or describe your current challenge). I’ll recommend the fastest route—mentorship, workshop, outsourced review support, or governance/SOP build—and what success looks like in the next 2–4 weeks.
Insights and more
News & PMCPA Cases

AI-Enabled MLR in Pharma: Governance First Guide
AI tools can enhance Medical affairs MLR workflows but pose governance challenges. It’s crucial to implement strict controls, maintain compliance with the ABPI Code, and ensure documented human oversight.
AstraZeneca: promotional meeting misclassified and LinkedIn ‘likes/reposts’ led to pre-authorisation promotion and public advertising concerns (AUTH/3729/1/23)
Six complaints against AstraZeneca. Breaches found for a UK meeting treated as non-promotional (certification/PI and ‘cure’ claims) and for LinkedIn engagement promoting an unlicensed medicine and a POM to the public.

Blurred boundaries: Lessons from the Eli Lilly Facebook Breast Cancer Ad (CASE/3869/12/23)
TL;DR: Even a globally reputable company using trusted partners can stumble into serious compliance breaches online. All pharma professionals should be proactive, transparent, and vigilant—especially with third-party digital campaigns. The

The ripple effect of a single click: What Moderna’s mRESVIA PMCPA case really teaches us
Ever wondered how something as innocent as a LinkedIn ‘like’ could pull an entire pharma company into PMCPA hot water? I once underestimated how quickly a digital echo can travel,

LinkedIn landmines: The hidden pitfalls of pharma social media
What 214 Social Media cases taught me about compliance risk I’ve just finished reviewing 214 PMCPA cases where social media played a role. The pattern is undeniable: LinkedIn and other

Beyond the headlines: What the Epidyolex Press Release ruling really teaches pharma teams
Let me take you behind the scenes of a Jazz Pharmaceuticals case that could have happened to any of us. In my early years as a final signatory I found
